Becton Dickinson clear analyst focus, shares trade steadily in the S&P 500
23.06.2026 - 20:06:17 | ad-hoc-news.de
By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-23, 20:05.
Becton Dickinson and Company (US0758871091) remains in focus on the NYSE, with the S&P 500 constituent’s shares recently changing hands in the mid-140 dollar range after a muted three-year performance versus the wider index, according to price data aggregators and analyst commentary. The current discussion centers on how analysts rate the medtech group after a recent target cut by Bank of America and persistent sector headwinds.
What analysts are signaling now
Analysts at Bank of America trimmed their price target for Becton Dickinson shares in mid-June 2026, citing ongoing medtech headwinds and a less favorable risk-reward profile for some procedure-dependent product lines, as reported by German finance portal finanzen.net referencing the U.S. bank’s research note.Bank of America update via finanzen.net The bank nonetheless continues to view BD as a core name within large-cap medical technology, highlighting its diversified portfolio in diagnostics, medical devices and interventional products.
Across the Street, consensus data from MarketScreener indicates that a solid majority of covering houses still rate Becton Dickinson at Buy or Outperform, while the average 12?month price target sits noticeably above the current share price, pointing to a perceived upside from current levels.MarketScreener consensus overview At the same time, several brokers have recently adopted more cautious wording around hospital capital budgets and procedure volumes, which could weigh on near-term growth.
How the valuation and history compare
According to stock history platform StockScan, Becton Dickinson shares most recently closed at around 145.43 dollars on June 23, 2026, implying a marked discount to the all-time high of 287.32 dollars reached in July 2023.StockScan price history for BDX That translates into a roughly 49 percent decline from the peak, underscoring the more challenging phase medtech has experienced as procedure growth normalized and cost pressures increased.
On the European side, the Becton, Dickinson share quoted in euros on platforms such as finanzen100 recently traded around 123 euros, reflecting the same underlying valuation trend for euro-based investors.Finanzen100 listing in euros With Becton Dickinson grouped in the medical equipment segment and part of the U.S. S&P 500 index, investors often compare its performance with peers such as Medtronic and Abbott Laboratories when assessing relative value and sector positioning.
All news and analysis on the Becton Dickinson shares
Track current reports, historical performance and further analyst opinions on Becton Dickinson in the dedicated topic section and via the company’s Investor Relations hub.
Where Becton Dickinson makes its money
Becton Dickinson generates revenue across three main segments: BD Medical, BD Life Sciences and BD Interventional, supplying hospitals, laboratories and clinicians worldwide with devices and systems used in medication management, diagnostics and minimally invasive procedures, according to the company profile on its Investor Relations site.BD company overview Within this portfolio, products such as prefillable syringes, vascular access devices and diagnostic instruments form recurring revenue streams tied closely to global healthcare utilization.
Where the stock trades today
The Becton Dickinson shares (US0758871091) most recently traded around 145.43 dollars on the NYSE on 2026-06-23, 20:00, according to StockScan data, corresponding to approximately 123 euros on German trading platforms at the same time.
Key data on the Becton Dickinson shares
- Company: Becton, Dickinson and Company
- ISIN: US0758871091
- WKN: 857675
- Ticker: BDX
- Trading venue: NYSE
- Price (as of 2026-06-23, 20:00): 145.43 USD
- Market cap: 42.0 billion USD (as of 2026-06-23)
- Sector / industry: Health Care / Medical Equipment
- Index membership: S&P 500
- Next earnings date: 2026-08-01
This article is for informational purposes only and does not constitute investment advice, a recommendation to buy or sell any security, or any other form of financial guidance. Investors should conduct their own research or consult a qualified advisor before making investment decisions.
